State of the Art and New Perspectives for Non-Invasive Point-of-Care Testing

Abstract

Point-of-care (POC) analytical technology has empowered patients with a more convenient, rapid, reliable, and cost-effective diagnostic tool for self-management of health. In order to realize the effective disease management and appropriate therapeutic interventions in real time, there is a great need for a POC health monitoring system which allows non-invasive, accurate, convenient, easy-to-use, painless, and very fast measurements. By reviewing some current technologies of POC, we believe for the next generation of POC testing, home testing devices with non-invasive testing approach, accurate results, and real-time measurements will be the new trends.

Keywords: Cancer; Chronic disease; Point-of-Care; Non-invasive; Healthcare; Home testing

Introduction

Point-of-care (POC) testing enables rapid diagnosis or monitoring of chronic conditions that can facilitate clinical decisions. Such technologies have potential to significantly change the healthcare and diagnostic pathways. Patients can obtain immediate results in hospital, physician’s office, or even at home. This approach saves patients’ tremendous amount of time, resulting in a faster application of efficient treatment or referral for further investigation. Nowadays, POC devices are well established in clinical practice for early detection and management of disease [1]. Several well-known applications include the in-home blood glucose monitoring system for diabetes management [2], the prothrombin time test for anti-coagulation level measurement [3,4], and the pregnancy test [5], to name a few. However, most of the approaches are invasive process which involves the use of blood. Patients are usually unwilling to conduct blood test due to annoying pains and massive scarring formation that is developed from finger pricks or blood draw. These disadvantages hinder POC technologies from more extensive application in prospect. Thus, the aim of this review is to reveal the future trends for POC technologies, which is the real-time and non-invasive disease diagnosis and monitoring system for home use. Furthermore, the cost-effective point-of-care testing (POCT) devices should possess comparable accuracy and sensitivity to conventional hospital laboratory analyzers, so reliable results can empower patients to track their health progress (Figure 1).

Discussion

POC testing has already been utilized for screening patients from cancers and other chronic diseases. According to cancer facts and figures 2016, nearly 600 thousand Americans are expected to die of cancer in 2016, which translates to about 1,630 people per day [6]. It is essential to diagnose cancers at their early stages before it had the chance to get too big or spread, so the improvement in survival reflects both the earlier diagnosis of certain cancers and improvements in treatments. It would have saved millions people’s lives if an early warning system of cancers are available. In addition, the prevalence of chronic diseases is drawing billions cost from the government budget for health care each year [7], and such huge burden can be mitigated if the non-invasive POC testing system can help monitor disease-related biomarkers for disease monitoring and control. The real-time results will dramatically decrease the time for diagnosis and institutional treatment, reduce in-patient hospital stay, eliminate laboratory test analysis, and improve cost-effectiveness. Such
A mini continuous blood glucose monitor developed jointly by DexCom and Google can be attached to the skin in contact with subcutaneous tissue and measure sugar levels in interstitial liquid [11]. With a price of $150, the selling point of the device is the accessibility of real-time glucose data for diabetes management. However, it is not approved by the U.S. food and drug administration (FDA) to stand alone as a reliable blood glucose monitoring method. [12-14] Compared to fingertip blood tests, the interstitial liquid test is minimal invasive and causes less discomfort to patients. Nevertheless, it is still not an ideal approach due to its potential side effects, such as skin irritation and infections. Thus, latest generations are focusing on transferring this technology into more user-friendly disposable devices, such as bandage and contact lens [15].

Optical detector

Targeting on the non-invasive glucose detection, Bio control Technology Inc. attempted to use infrared light by illuminating the light on patients’ arm, and then collecting the light which scattered back out through the skin for measurement. Nevertheless, this tissue spectroscopy method has low signal-to-noise ratio, and signal is easily interfered by physiological changes of each individual [16]. Without a FDA approval, accuracy is always the critical factor for POC use. Another non-invasive blood analyte monitoring device, the NBM 200 system, was developed by Or Sense. Routine operation can be performed by combining the optical measurement platform with a finger attached ring-shape sensor probe. By temporarily occluding blood flow in the finger, a newly created blood dynamics can generate informative transmission signal across the finger. The product has received CE and CDN approval and received FDA 510(k) clearance in 2013 for non-invasive hemoglobin testing. This is a huge step forward as non-invasive disorders monitoring systems. A couple technologies are introduced and compared as examples to discover future perspectives of POC applications (Table 1).

Saliva-based sensing system

Recently, a non-invasive method using saliva as an indicative fluid is being explored to manage chronic diseases [17,18]. Using saliva for disease diagnostics and health surveillance is a promising approach since saliva has been found to contain constituents that reflect the diseased or physiological state of the human body [19-21]. A genetic screening test, called color genomics, is offering an at-home DNA saliva test to detect gene mutations linked to breast and ovarian cancer. Instead of one single biomarker analysis, the comprehensive analysis of 30 genes endow this technology with a more rigorous determination. Unfortunately, the expensive $250

Table 1: Comparative aspects of point-of-care testing (POCT) devices.

<table>
<thead>
<tr>
<th>Product</th>
<th>Characterizations</th>
<th>Company</th>
<th>Technology</th>
<th>Device Certification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexcom Continuous Glucose Monitor System</td>
<td>Minimally Invasive Real-Time</td>
<td>Dexcom &amp; Google</td>
<td>Enzyme-Base Electrochemical Sensor</td>
<td>No</td>
</tr>
<tr>
<td>Gluco-Watch</td>
<td>Non-Invasive Real-Time</td>
<td>Bio Control Technology Inc.</td>
<td>Near Infrared Transmission Spectroscopy</td>
<td>No</td>
</tr>
<tr>
<td>Nbs 200</td>
<td>Non-Invasive Real-Time</td>
<td>Or Sense</td>
<td>Occlusion Technology</td>
<td>Ce, Cdn, Fda 501(K)</td>
</tr>
<tr>
<td>Color Genomics Kit</td>
<td>Non-Invasive Requires Laboratory Tests</td>
<td>Color Genomics Inc.</td>
<td>Sequencing Technology</td>
<td>CAP &amp; CLIA</td>
</tr>
<tr>
<td>Oraquick Advance Rapid HIV-1/2 Antibody</td>
<td>Non-Invasive Real-Time</td>
<td>OraSure Technologies Inc.</td>
<td>Enzyme Immunoassays</td>
<td>FDA CLIA-Waived</td>
</tr>
</tbody>
</table>

Minimally invasive devices

A mini continuous blood glucose monitor developed jointly by DexCom and Google can be attached to the skin in contact with subcutaneous tissue and measure sugar levels in interstitial liquid [11]. With a price of $150, the selling point of the device is the accessibility of real-time glucose data for diabetes management. However, it is not approved by the U.S. food and drug administration (FDA) to stand alone as a reliable blood glucose monitoring method. [12-14] Compared to fingertip blood tests, the interstitial liquid test is minimal invasive and causes less discomfort to patients. Nevertheless, it is still not an ideal approach due to its potential side effects, such as skin irritation and infections. Thus, latest generations are focusing on transferring this technology into more user-friendly disposable devices, such as bandage and contact lens [15].
test kit is still a step away from the real POC. Although consumers can collect their saliva sample easily and non-invasively at home, they need to mail the sample out for analysis. Here, the real-time diagnostic result or test report is still missing.

On the other hand, a more successful and relatively mature saliva-based test kit was launched by OraSure Technologies, Inc. in early 21st for the in-home HIV test. A quick home testing using Ora Quick Advance Rapid HIV-1/2 Antibody can reveal results within 20 minutes. Furthermore, the oral fluid detection was approved by FDA in 2002, and an average sensitivity of 95% and specificity of 99.8% verified from the screening tests. [22] Despite its inspiring performance, a long list of limitations of the test also indicates the difficulties to control accuracy in real practice [23]. However, it gives us an idea about how critical the two factors: accuracy and real-time performance can affect the prosperity of similar technologies for POC testing.

Conclusion

Overall, new trends are formed in the POC setting that hammer at high accuracy, sensitivity, convenience, reliability, non-invasion, and most importantly, the real-time measurements of disease-related biomarkers. The non-invasive monitoring technology offers patients a simple and fast way to measure the real-time disease-related biomarker levels frequently as needed with no pain, stress-free, no risk of infection, and non-scarring. For the future perspectives of POC applications, accurate home testing, non-invasive testing, and real-time performance would be the key factors to evaluate the feasibility of the developed technology. To fulfill the objectives, future research and publications need to focus on studying or guiding the standard accuracy and capabilities of non-invasive POC technologies to the home setting. These contributions would certainly help push technology forward and improve health outcomes through self-management.

References

3. Heu M, Weborn T, Nagykaldi Z (2016) In adult patients on warfarin, does home self-testing of prothrombin time and/or international normalized ratio provide the same outcomes compared to testing by a home health nurse or in a clinical setting? Journal of Oklahoma State Medical Association 109(3): 99-100.
13. FDA (2015) Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision.
15. (2015) Google and Dexcom Team Up to Dramatically Improve CGM.